IP Library Granted Patent US 9,706,900
Granted Patent B2
US 9,706,900 · App. 13/919,073 · Granted Jul 18, 2017

Systems, apparatus and associated methods for needleless delivery of therapeutic fluids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,706,900
App. No.
13/919,073
Granted
Jul 18, 2017
Kind
B2
Abstract

A needleless fluid delivery system for delivering therapeutic fluids to treatment sites within a patient. The fluid delivery system can include an automated injector source and a needleless access device. The access device can include a delivery scope and a treatment specific applicator. The automated injector source, delivery scope and applicator can be operably coupled with quick-connect style fittings so as to allow for quick replacement and maintenance of used or damaged components. The automated injector source can include a hands-free input mechanism allowing a medical professional to use both hands in manipulating the delivery scope and needleless applicator at the same time an injection is desired. The delivery scope and needleless applicator can comprise flexible or rigid lengths of tubing based on the accessibility of the treatment site. The needleless delivery system can include an imaging system for precisely position the applicator with respect to the treatment location.

Claims (20)

1. A method for delivery a therapeutic fluid to a treatment location comprising:

providing at least one treatment-specific applicator comprising an applicator head having a head delivery lumen and a head vacuum lumen, wherein the at least one treatment-specific applicator is configured for use at a specific treatment location,

providing a flexible scope comprising a scope delivery lumen and a scope vacuum lumen,

advancing the flexible scope through the treatment-specific applicator until the scope delivery lumen is fluidly connected to the head delivery lumen and the scope vacuum lumen is fluidly connected to the head vacuum lumen

accessing a treatment location with the treatment-specific applicator;

connecting the treatment-specific applicator to a connector member of a needleless fluid delivery system including an automated injector such that the automated injector preconfigures a controller for standard operating conditions associated with the treatment-specific applicator;

initiating the scope vacuum lumen and head vacuum lumen to draw tissue at the treatment location to the head delivery lumen, and

delivering a therapeutic fluid from the flexible scope at operating conditions associated with the treatment-specific applicator.

2. The method of claim 1 , wherein the automated injector further comprises a touch screen, and delivering a therapeutic fluid comprises interfacing with the touch screen on the automated injector.

3. The method of claim 1 , wherein the automated injector further comprises a foot pedal, and delivering a therapeutic fluid comprises stepping on the foot pedal operably connected to the automated injector.

4. The method of claim 1 , wherein connecting the treatment-specific applicator to the needleless fluid delivery system, further comprises:

mechanically connecting the at least one treatment-specific applicator to the controller.

5. The method of claim 1 , wherein connecting the treatment-specific applicator to the needleless fluid delivery system further comprises:

electronically communicating the at least one treatment-specific applicator to the controller.

6. The method of claim 1 , further comprising:

confirming the proximity of the treatment-specific applicator to the treatment location with a medical imaging system.

7. The method of claim 1 , wherein the applicator head has an end fire injection lumen, and wherein delivering the therapeutic fluid further comprises administering the therapeutic fluid through the end fire injection lumen.

8. The method of claim 1 , wherein the applicator head has a side fire injection lumen, and wherein delivering the therapeutic fluid further comprises administering the therapeutic fluid through the side fire injection lumen.

9. The method of claim 1 , wherein the at least one treatment-specific applicator comprises a microchip or a RFID tag capable of communicating with the controller.

10. The method of claim 1 , wherein the at least one treatment-specific applicator is configured for treatment locations selected from a rectal treatment location, a gastrointestinal treatment location, a nasal treatment location, a bronchial treatment location, or an esophageal treatment location.

Assignments (13)
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.); ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0795 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR PHARMACEUTICAL COMPANIES, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0491 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR PHARMACEUTICAL COMPANIES, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0542 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 17, 2021
From: ASTORA WOMEN'S HEALTH LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS INC.; PAR PHARMACEUTICAL, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 057538/0978 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Apr 6, 2021
From: BIOSPECIFICS TECHNOLOGIES LLC; PAR PHARMACEUTICAL, INC.; AUXILIUM US HOLDINGS, LLC; ASTORA WOMEN'S HEALTH, LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 055845/0618 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Apr 6, 2021
From: BIOSPECIFICS TECHNOLOGIES LLC; PAR PHARMACEUTICAL, INC.; AUXILIUM US HOLDINGS, LLC; ASTORA WOMEN'S HEALTH, LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 055846/0246 →
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: ENDO PHARMACEUTICALS, INC.; ENDO PHARMACEUTICALS SOLUTIONS, INC.; ASTORA WOMEN'S HEALTH HOLDINGS, LLC
Reel/Frame 042362/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2017
From: AMERICAN MEDICAL SYSTEMS, LLC
To: AMERICAN MEDICAL SYSTEMS HOLDINGS, INC.
Reel/Frame 042092/0559 →
CHANGE OF NAME Recorded Apr 21, 2017
From: ASTORA WOMEN'S HEALTH, INC.
To: ASTORA WOMEN'S HEALTH HOLDINGS, LLC
Reel/Frame 042310/0682 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2017
From: AMS RESEARCH, LLC
To: AMERICAN MEDICAL SYSTEMS, LLC
Reel/Frame 042092/0417 →
CHANGE OF NAME Recorded Apr 21, 2017
From: AMS RESEARCH CORPORATION
To: AMS RESEARCH, LLC
Reel/Frame 042310/0335 →
CHANGE OF NAME Recorded Apr 21, 2017
From: AMERICAN MEDICAL SYSTEMS HOLDINGS, INC.
To: ASTORA WOMEN'S HEALTH, INC.
Reel/Frame 042310/0640 →
GRANT OF SECURITY INTEREST IN PATENTS Recorded Mar 20, 2014
From: ENDO PHARMACEUTICALS SOLUTIONS, INC.; ENDO PHARMACEUTICALS, INC.; AMS RESEARCH CORPORATION; AMERICAN MEDICAL SYSTEMS, INC.; LASERSCOPE
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032491/0440 →